Exon 20 Group, a multistakeholder organization
@Exon20Group
Global org: patients/carers, HCPs, pharma, labs, scientists, working to cure #NSCLC #HER2 & #EGFR #Exon20 insertions (in 25 cancers +) [email protected]
Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services,…
It’s official! 🎉 Excited and honored to be joining the @StanfordMed @StanfordCancer Head & Neck Med Onc faculty 👩🏫 this fall. So much gratitude 🙏 to the many mentors who have supported me along the way @ADColevasMD @JoelNealMD @DasMillie11 @HwakeleeMD @tpjmd
The concept of treatment beyond progression is indeed intriguing. It challenges traditional paradigms and opens doors to personalized approaches in managing progression. How do you think this approach impacts long-term outcomes in comparison to switching therapies entirely? For…
At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled
#Exon20 Group @Exon20Group and our #EGFR #Exon 20 Warriors and #HER2 Warriors send congratulations on your exciting new role, @StephenVLiu !
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
Top 10 #LungCancer Oncologists for June 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | @StephenVLiu | @HHorinouchi |…
How should clinicians approach resectable EGFR-mutant #NSCLC? On the latest #LungCancerConsidered episode, @StephenVLiu moderates a case discussion with @collin_blakely and @susu_mail0513, covering evolving strategies and clinical decision-making. 🎧 bit.ly/VTBregfrnsclc
More great news for patients with rare mutations: @FDAOncology approved today #Sunvozertinib (Zegfrovy) oral TKI for #EGFR20ins #lungcancer after platinum chemo: a big area of unmet need. 🎯WU-KONG1B trial 💊200mg once a day 🎯 ORR 46% DOR 11.1 mos ⚠️AEs: Diarrhea (17%), CPK…
FDA grants accelerated approval to sunvozertinib (200mg po qd) for EGFR exon 20 insertion NSCLC after chemotherapy. In WU-KONG1B, RR 46%, mDOR 11.1m - important AEs include ILD, diarrhea, rash. Welcome addition with several others also in development. fda.gov/drugs/resource…
New @US_FDA accelerated approval: Sunvozertinib for EGFR exon20ins NSCLC after platinum chemo ▫️n=85, WU-KONG1B ▫️ORR: 46% ▫️DoR: 11.1 mo ⚠️ Diarrhea, rash, ⬆️ CK @OncoAlert @Exon20Group #lcsm
Sunvozertinib (oral EGFR inhibitor, 200mg Qd) now @US_FDA approved based off PhII WU-KONG1 in previously treated Exon20ins mNSCLC: - Confirmed 44.9% ORR w/ 9mos DoR: 57% - ≥Gr 3: Diarrhea (17%), CPK levels (11%), and anemia (3.6%) #OncTwitter #MedTwitter
Delighted to see the FDA approval of #sunvozertinib, #Dizal Pharma's TKI, for #EGFR #Exon20 patients! Congratulations to the patients, care partners, investigators and #WuKong study teams!
Another brilliant talk from #DavaLung Co-Chair @Jsabari whose expertise @nyulangone in both EGFR and HER2 exon 20 has continued to assist countless patients and their family members. A role model for everyone else! COCOON has been the standard of care since ELCC 2025 and…
Dr. @Jsabari (@nyulangone) presents a deep dive on amivantamab + lazertinib in EGFRm NSCLC at #DAVALung, highlighting efficacy from MARIPOSA and the importance of proactive dermatologic care to manage its unique AE profile.
#HawaiiLung25 @christinemphmd @WeillCornell presents on the possibilities of incorporating large real world data, NLP to improve cancer care delivery for underserved populations. @DAVAOnc
Dr. Heather Wakelee (@HwakeleeMD) discussed evolving outcomes with ICIs in NSCLC. IMpower010 shows DFS benefit in KRAS G12C, BRAF, TP53, METex14. OS benefit remains limited in EGFR, KRAS G12D. EGFR+ data from IMpower151, others reaffirm minimal IO impact. #DAVALung
Sunvozertinib is missing!
✅ FDA Accelerated Approval Alert – June 23, 2025 The FDA has granted accelerated approval to Datroway (datopotamab deruxtecan-dlnk, Daiichi Sankyo) for adults with EGFR-mutated advanced NSCLC who’ve previously received EGFR therapy and platinum chemo. Approval is based on data…
Zongertinib has the mildest side effects of any drug—ever—in the Exon 20 Group, and our HER2 Warriors cannot praise it enough. So grateful to John Heymach for being international PI of the practice-changing zongertinib study. #DAVALung
Dr. John Heymach presents latest data with zongertnib in HER 2 mutant NSCLC. #DAVAlung
Great #DAVALung talk on MARIPOSA. And with @jillfeldman4 compelling presentation at ASCO 2025 on tox-mitigating strategies in the COCOON trial for amivantamab/lazertinib, MARIPOSA is a very sound option for life extension. Med oncs who are not familiar with ami/laz: Please…
Dr. @Jsabari (@nyulangone) presents a deep dive on amivantamab + lazertinib in EGFRm NSCLC at #DAVALung, highlighting efficacy from MARIPOSA and the importance of proactive dermatologic care to manage its unique AE profile.
Excellent presentation from @chulkimMD on NVL-330 and HEROEX-1–more clinical trial sites needed in the U.S. and abroad. #DAVALung
Promising developments in #lungcancer! @chulkimMD of @Georgetown discusses NVL-330 for HER2-altered NSCLC, preclinical tumor regression up to 83%, intracranial activity vs. T-DXd, and early clinical insights from the ongoing HEROEX-1 trial. #DAVALung #NSCLC
FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects. ascopost.com/news/june-2025…
Another advance for NSCLC EGFR-mutated lung cancer! Please contact us at the Exon 20 Group if you’ve been on Dato & you are #EGFR #Exon20 Insertion. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC | FDA fda.gov/drugs/resource…
